The purpose of this funding opportunity announcement (FOA) is to fund innovative research that will strengthen and advance minority health and health equity research.
Donor Name: Food and Drug Administration (FDA)
State: All States
County: All Counties
Type of Grant: Grant
Deadline: 05/08/2023
Size of the Grant: $250,000
Grant Duration: 1 year
Details:
The FDA Office of Minority Health and Health Equity (OMHHE) serves to promote and protect the health of diverse populations through research and communication of science that addresses health disparities. The purpose of this funding opportunity announcement (FOA) is to support innovative research that will strengthen and advance minority health and health equity research. Definition of Equity: “The consistent and systematic fair, just, and impartial treatment of all individuals, including individuals who belong to underserved communities that have been denied such treatment, such as Black, Latino, Indigenous and Native American persons, Asian Americans and Pacific Islanders and other persons of color; members of religious minorities; lesbian, gay, bisexual, transgender, and queer (LGBTQ+) persons; persons with disabilities; persons who live in rural areas; and persons otherwise adversely affected by persistent poverty or inequality.” Definition of Underserved Communities: “The populations sharing a particular characteristic, as well as geographic communities, that have been systematically denied a full opportunity to participate in aspects of economic, social, and civic life, as exemplified by the list in the preceding definition of ‘equity.’
Research Objectives
These efforts focus on advancing innovative research that will strengthen and advance minority health and health equity research. Including:
- Proposals that advance diversity in clinical trials including efforts that (a)identify barriers to enrollment for underrepresented populations (e.g. racial and ethnic minorities), (b) advance evidence for racial and ethnic clinical trial data, (c) employ innovative strategies/trainings/education methods to increase enrollment for underrepresented populations in clinical trials (e.g. racial and ethnic minorities), and/or (d) improve communication strategies and informed messages for underrepresented populations (e.g. racial and ethnic minorities).
- Proposals that advance equity in data including efforts that (a) increase evidence to support evaluation of outcomes of FDA-regulated products by demographic data including, but not limited to, ethnicity, race, age, and geography, and/or (b) leverage big data, novel data sources and artificial intelligence/machine learning options to contribute to informing the continued evaluation of the safety and efficacy of FDA-approved products (e.g., therapeutics, diagnostics, and vaccines).
- Proposals that increase understanding of diverse voices, including efforts that (a) support research to leverage novel data sources to understand diverse patient preferences and unmet needs, and/or (b) support expansion of culturally and linguistically tailored education (e.g., patient, healthcare providers).
The following studies are encouraged under this FOA:
- Improve and increase understanding of how racial and ethnic minority populations and other diverse groups engage on issues related to biological products including vaccines, allergenics, blood and blood products, tissues, cell and gene therapies (e.g., Center for Biologics Evaluation and Research).
- Improve and increase understanding of how racial and ethnic minority populations and other diverse groups engage with FDA OMHHE.
- Advance understanding of demographic characteristics, health impacts and treatment outcomes of rare diseases and conditions that affect racial and ethnic minority populations living with rare diseases in the United States. Such studies should focus on rare disease, e.g., ALS, or a group of related rare diseases, e.g., motor neuron disease (MND) variants, in the United States.
- Insights will contribute to better understanding of the health disparities among racial and ethnic minority populations living with rare diseases. This information will contribute to understanding the diagnostic odyssey, care at multidisciplinary centers of excellence and barriers to clinical trial participation and access.
- Increase understanding of climate change on the impact of treatment outcomes among racial and ethnic minority populations (e.g., Asthma).
Funding Information
- The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support.
- FDA’s Office of Minority Health and Health Equity (OMHHE) intends to fund up to $1,000,000 for fiscal year 2023 in support of this cooperative agreement program.
- It is anticipated that up to four (4) awards will be made, not to exceed $250,000 in total costs (direct plus indirect) per award.
Project Period: The scope of the proposed project should determine the project period. The maximum project period is ONE (1) year.
Eligible Applicants
- Native American tribal governments (Federally recognized)
- Public and State controlled institutions of higher education
- City or township governments
- County governments
- Independent school districts
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- Small businesses
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- State governments
- Special district governments
- Private institutions of higher education
- Public housing authorities/Indian housing authorities
- For profit organizations other than small businesses
For more information, visit Grants.gov.
